HALT-C trial group showed in their randomized control trial in a large cohort that long-term PEG-IFN-α2a therapy does not reduce the incidence of HCC among patients with chronic HCV infection who have previously failed to achieve a sustained virologic response to therapy [30]. This evidence concerns the gene IFNA2 and hepatocellular carcinoma.